AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7771828 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (37 degrees C)
Number of subjects: 0
Study 7771828 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (28 degrees to 30 degrees C)
Number of subjects: 0
Study 7771828 — intervention group
Group type: COMPARATOR
Intervention: Cold group (hypothermic)
Number of subjects: 0
Study 7771828 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm group (normothermic)
Number of subjects: 0
Study 7771828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 0
Study 2150312 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0
Study 2150312 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 0
Study 2150312 — intervention group
Group type: COMPARATOR
Intervention: Thrombocytopenia
Number of subjects: 0
Study 108461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.6 to 6.0 mg/h, mean 2.3 mg/h) over 48 hours
Number of subjects: 38
Study 108461 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific therapy)
Number of subjects: 38
Study 31955285 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool nested PCR
Number of subjects: 100
Study 31955285 — intervention group
Group type: COMPARATOR
Intervention: Stool microscopy
Number of subjects: 100
Study 31955285 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool PCR
Number of subjects: 100
Study 31955285 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal biopsy PCR
Number of subjects: 100
Study 31248113 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 800
Study 31248113 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity in women
Number of subjects: 800
Study 31248113 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity with better health literacy
Number of subjects: 800
Study 27997263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) supplementation (140ml of NO3‐rich beetroot juice containing 8.0mmol [NO3‐] for seven days)
Number of subjects: 9
Study 27997263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) supplementation
Number of subjects: 9
Study 27997263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 26914336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tzu-Yun Ointment (TYO)
Number of subjects: 33
Study 26914336 — intervention group
Group type: COMPARATOR
Intervention: Topical Steroids (TS)
Number of subjects: 33
Study 24873022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejected group
Number of subjects: 54
Study 24873022 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 24873022 — intervention group
Group type: EXPERIMENTAL
Intervention: Accepted group
Number of subjects: 54
Study 22095398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine (RG7128) 750 mg administered bid
Number of subjects: 32
Study 22095398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine (RG7128) 1500 mg administered bid
Number of subjects: 32
Study 22095398 — intervention group
Group type: COMPARATOR
Intervention: Mericitabine (RG7128) administered qd
Number of subjects: 32
Study 19566665 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly re-treatment
Number of subjects: 226
Study 19566665 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept re-treatment
Number of subjects: 226
Study 17685691 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CRE)
Number of subjects: 25
Study 17685691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 25
Study 15458988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 58
Study 15458988 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 58
Study 11880809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HIFAT)
Number of subjects: 7
Study 11880809 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (HICHO)
Number of subjects: 7
Study 10090548 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of fever episodes
Number of subjects: 155
Study 10090548 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at study entry
Number of subjects: 155
Study 10172279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol
Number of subjects: 43
Study 10172279 — intervention group
Group type: COMPARATOR
Intervention: Anesthetist-controlled sedation (ACS)
Number of subjects: 43
Study 2104972 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 30) - Predictive equations for TBW
Number of subjects: 44
Study 2104972 — intervention group
Group type: COMPARATOR
Intervention: Group II (n = 14) - Cross-validation of predictive equations
Number of subjects: 44
Study 323316 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanamycin gel treatment for one week before and after dental restorations
Number of subjects: 0
Study 323316 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel treatment
Number of subjects: 0
Study 31454295 — intervention group
Group type: EXPERIMENTAL
Intervention: Response adaptive randomization procedures in seamless phase II/III clinical trials
Number of subjects: 0
Study 30076459 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention consisting of dietary counseling, physical activity, and behavioral modification
Number of subjects: 0
Study 30076459 — intervention group
Group type: COMPARATOR
Intervention: Previous dietetic support
Number of subjects: 0
Study 30076459 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-efficacy
Number of subjects: 0
Study 30076459 — intervention group
Group type: EXPERIMENTAL
Intervention: Older partner
Number of subjects: 0
Study 30076459 — intervention group
Group type: EXPERIMENTAL
Intervention: High stage of change towards physical activity
Number of subjects: 0
Study 30076459 — intervention group
Group type: EXPERIMENTAL
Intervention: High stage of change towards weight loss
Number of subjects: 0
Study 28605468 — intervention group
Group type: EXPERIMENTAL
Intervention: X358 (0.1-9 mg/kg)
Number of subjects: 29
Study 28605468 — intervention group
Group type: EXPERIMENTAL
Intervention: X358 (3-9 mg/kg)
Number of subjects: 29
Study 28605468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25441954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-containing meal (30% of calories as fat)
Number of subjects: 50
Study 25441954 — intervention group
Group type: COMPARATOR
Intervention: Fat-free meal
Number of subjects: 50
Study 25441954 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal with low MUFA:PUFA ratio (1:4)
Number of subjects: 50
Study 25441954 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal with high MUFA:PUFA ratio (4:1)
Number of subjects: 50
Study 23567505 — intervention group
Group type: EXPERIMENTAL
Intervention: Leave‐One‐Out procedure
Number of subjects: 33
Study 23567505 — intervention group
Group type: COMPARATOR
Intervention: Split half approach
Number of subjects: 33
Study 21281461 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (Group CBT) sessions
Number of subjects: 96
Study 21281461 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 96
Study 19628366 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 14
Study 19628366 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 14
Study 19628366 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 14
Study 19628366 — intervention group
Group type: COMPARATOR
Intervention: Pentasaccharides
Number of subjects: 14
Study 16199793 — intervention group
Group type: EXPERIMENTAL
Intervention: Family education
Number of subjects: 101
Study 10470568 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSVtc (time-cycled inspiratory pressure support ventilation)
Number of subjects: 6
Study 10470568 — intervention group
Group type: COMPARATOR
Intervention: NIPSVfc (flow-cycled inspiratory pressure support ventilation)
Number of subjects: 6
Study 10470568 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSVtc
Number of subjects: 6
Study 9005797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice a day for 3 to 5 days, followed by oral use of the same dosage for 3 to 5 days)
Number of subjects: 200
Study 9005797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg once a day for 3 to 5 days)
Number of subjects: 200
Study 9005797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (same dosage as above for 10 days)
Number of subjects: 200
Study 9005797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (prophylactic use)
Number of subjects: 200
Study 1947265 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastromiro
Number of subjects: 818
Study 1947265 — intervention group
Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 818
Study 1947265 — intervention group
Group type: COMPARATOR
Intervention: Prontobarium‐CT
Number of subjects: 818
Study 7047171 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoperidine (2 mg i.v.)
Number of subjects: 200
Study 7047171 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (t mg i.v.)
Number of subjects: 200
Study 7047171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study 31547291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar beet pectin (15 g/day)
Number of subjects: 100
Study 31547291 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 100
Study 30073224 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg consumption (one large egg per day)
Number of subjects: 42
Study 30073224 — intervention group
Group type: COMPARATOR
Intervention: Egg substitute
Number of subjects: 42
Study 27109459 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Ventilation (MV)
Number of subjects: 48
Study 27109459 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 48
Study 27109459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 48
Study 25146586 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg, open-label, every 4 weeks for up to 7 years (total of 91 doses)
Number of subjects: 595
Study 25146586 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 595
Study 22029576 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine ointment after phacoemulsification
Number of subjects: 400
Study 22029576 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 400
Study 22029576 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine ointment
Number of subjects: 400
Study 19452483 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment with atorvastatin (maximum 80 mg/d)
Number of subjects: 1001
Study 19452483 — intervention group
Group type: COMPARATOR
Intervention: Usual care (continuation of baseline lipid-lowering therapy)
Number of subjects: 1001
Study 16721618 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Number of subjects: 157
Study 16721618 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Number of subjects: 157
Study 16721618 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (20 ml Prilocain 1% + 20 ml Bupivacain 0.5%)
Number of subjects: 157
Study 16036026 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition (ACEI)
Number of subjects: 0
Study 16036026 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockade
Number of subjects: 0
Study 16036026 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone receptor blockade
Number of subjects: 0
Study 12432502 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg130Gln polymorphism of the IL‐13 gene
Number of subjects: 685
Study 10723508 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine plus didanosine or lamivudine
Number of subjects: 0
Study 7645915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin) 40 mg once daily, starting 12 hours preoperatively for 10 days
Number of subjects: 167
Study 7645915 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 IU twice a day subcutaneously, starting two hours before operation for 10 days
Number of subjects: 167
Study 31134665 — intervention group
Group type: EXPERIMENTAL
Intervention: PG-SGA SF paper version
Number of subjects: 59
Study 31134665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pt-Global app
Number of subjects: 59
Study 31134665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 59
Study 30325305 — intervention group
Group type: EXPERIMENTAL
Intervention: 300mg of daily oral aspirin
Number of subjects: 27
Study 30325305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28075064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol-valsartan SPC (5/80 mg/d)
Number of subjects: 2670
Study 28075064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol or valsartan monotherapy
Number of subjects: 2670
Study 28075064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2670
Study 28075064 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (including SPCs, nebivolol, valsartan)
Number of subjects: 2670
Study 26638446 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 18144
Study 26638446 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 18144
Study 24469137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg/kg)
Number of subjects: 55
Study 24469137 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 55
Study 24469137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 55
Study 24469137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 21836103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 2503
Study 21836103 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 2503
Study 21836103 — intervention group
Group type: EXPERIMENTAL
Intervention: ILI
Number of subjects: 2503
Study 20111618 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin and Sulodexide
Number of subjects: 102
Study 20111618 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin alone
Number of subjects: 102
Study 20111618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study 17215657 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/d
Number of subjects: 170
Study 17215657 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg/d
Number of subjects: 170
Study 17215657 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ 40/12.5 mg/d
Number of subjects: 170
Study 17215657 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/HCTZ 40/25 mg/d
Number of subjects: 170
Study 17215657 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 170
Study 15316474 — intervention group
Group type: EXPERIMENTAL
Intervention: Halogen light curing for 20 seconds
Number of subjects: 30
Study 15316474 — intervention group
Group type: COMPARATOR
Intervention: Plasma arc light curing for 5 seconds
Number of subjects: 30
Study 11488316 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial dose of budesonide (800 microg b.i.d)
Number of subjects: 169
Study 11488316 — intervention group
Group type: COMPARATOR
Intervention: Standard initial dose of budesonide (200 microg b.i.d)
Number of subjects: 169
Study 9590413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 0
Study 9590413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg
Number of subjects: 0
Study 9590413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 0
Study 9590413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9590413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg or 40 mg (duodenal and gastric ulcer protocols)
Number of subjects: 0
Study 9590413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (all doses)
Number of subjects: 0
Study 9590413 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori positive status
Number of subjects: 0
Study 7921757 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol Marine (12 capsules daily for 9 months)
Number of subjects: 38
Study 7921757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 capsules daily for 9 months)
Number of subjects: 38
Study 7921757 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol Marine
Number of subjects: 38
Study 7921757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3246170 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular dose of ceftriaxone 50 mg/kg
Number of subjects: 52
Study 3246170 — intervention group
Group type: COMPARATOR
Intervention: 7 days of amoxicillin 12.5 mg/kg t.i.d.
Number of subjects: 52
Study 3246170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study 31747677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet HF (high-fat diet: 38% carbohydrates, 24% proteins, and 38% fats)
Number of subjects: 283
Study 31747677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet LF (low-fat diet: 53% carbohydrates, 20% proteins, and 27% fats)
Number of subjects: 283
Study 31747677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet HF
Number of subjects: 283
Study 31747677 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet LF
Number of subjects: 283
Study 30101580 — intervention group
Group type: EXPERIMENTAL
Intervention: elmex erosion protection toothpaste (group E2)
Number of subjects: 72
Study 30101580 — intervention group
Group type: EXPERIMENTAL
Intervention: R.O.C.S. toothpaste (group E3)
Number of subjects: 72
Study 30101580 — intervention group
Group type: EXPERIMENTAL
Intervention: R.O.C.S. medical minerals gel (group E3)
Number of subjects: 72
Study 30101580 — intervention group
Group type: EXPERIMENTAL
Intervention: R.O.C.S. toothpaste (group EA3)
Number of subjects: 72
Study 30101580 — intervention group
Group type: EXPERIMENTAL
Intervention: elmex erosion protection toothpaste (group EA2)
Number of subjects: 72
Study 30101580 — intervention group
Group type: COMPARATOR
Intervention: No additional toothpaste (control group E1)
Number of subjects: 72
Study 30101580 — intervention group
Group type: COMPARATOR
Intervention: No additional toothpaste (control group EA1)
Number of subjects: 72
Study 27994002 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency of response efficacy (specific health benefits accruing within 1 month)
Number of subjects: 1669
Study 27994002 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrogative cue ('Ready to be tobacco-free?')
Number of subjects: 1669
Study 27994002 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy manipulation
Number of subjects: 1669
Study 26653722 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAID treatment on the day of surgery in the femtosecond laser group
Number of subjects: 75
Study 26653722 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAID treatment on the day of surgery in the conventional cataract surgery group
Number of subjects: 75
Study 26653722 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser cataract surgery
Number of subjects: 75
Study 26653722 — intervention group
Group type: COMPARATOR
Intervention: Conventional cataract surgery
Number of subjects: 75
Study 22548378 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy (PFIT) - 12 weeks of individual child CBT plus 6 sessions of family treatment
Number of subjects: 20
Study 22548378 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST) - 12 weeks of individual child CBT with weekly parent check‐ins and psychoeducation
Number of subjects: 20
Study 21469215 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on mirtazapine 30 mg during a 6-week double-blind phase
Number of subjects: 41
Study 21469215 — intervention group
Group type: COMPARATOR
Intervention: Placebo during a 6-week double-blind phase
Number of subjects: 41
Study 21469215 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label add-on mirtazapine during a 6-week extension phase
Number of subjects: 41
Study 21469215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine during the double-blind phase
Number of subjects: 41
Study 18798752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC) with onion extract gel
Number of subjects: 27
Study 18798752 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TAC) alone
Number of subjects: 27
Study 16391903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 531
Study 16391903 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 531
Study 16391903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification plus Metformin (LSM + MET)
Number of subjects: 531
Study 16391903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 531
Study 14664677 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard mock-crime procedure
Number of subjects: 0
Study 14664677 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic mock-crime procedure
Number of subjects: 0
Study 14664677 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of GKT questions
Number of subjects: 0
Study 10965417 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination therapy comprising crataegus and camphor (Korodin Herz‐Kreislauf‐Tropfen)
Number of subjects: 190